Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2023 Earnings Call Transcript

Page 6 of 6

Let’s talk about how many patients we treat. Let’s talk about making sure that you’ve got message consistency, all those things.

Douglas Tsao: Okay, great. Thank you so much. That’s helpful.

Mark Foley: Great. Thanks, Doug.

Operator: We now turn to Terence Flynn with Morgan Stanley. Your line is open.

Terence Flynn: Hi, thanks for taking the question. I guess two, probably for Toby is just, you know, any more clarity on timing of how you’re thinking about the revenue guidance for 2024? Is that early January event? Is it in conjunction with fourth quarter results? Or is it later in the year? And then how should we think about the DAXXIFY gross margin progression as we head into 2024? Thank you.

Dustin Sjuts: Yes, great questions, Terence. So, we haven’t been specific on the timing of our guidance right now, except for the first half of 2024. And right now, we think that’s the appropriate guidance to give on that particular timing. Regarding sort of the gross margin profile, if you were to look at sort of our GAAP gross margin profile that was sort of reported in Q1, Q2, Q3, Revance’s GAAP gross margin has been pretty consistent about 73, 68, and 70-ish percent over the past several quarters. And again, that’s largely been, you know, the Q3, obviously, the mix between Q2 and Q3 of RHA and DAXXIFY was relatively the same Q2 versus Q3. And so, we had lower prices for DAXXIFY starting in September, but we were able to offset that with efficiencies that we were found through the supply chain to maintain that gross margin profile.

One of the things that as we start to utilize the prior approved product, the product that was expensed versus capitalized, we expect there will be some flux upwards on sort of the cost of goods sold for DAXXIFY. However, that will be partially offset by going into Aji and other manufacturers that are actually much cheaper on a unit economic perspective. So, we expect some fluctuation around the margin, but generally trying to offset those and the larger thing is making sure stabilizing prices.

Terence Flynn: Thank you.

Operator: Our last question comes from Navann Ty with BNP Paribas. Your line is open.

Navann Ty: Hi, good evening. Thanks for taking my question and thanks for the comment so far on the price change. Just some additional ones from me. Do you have an estimate on how long it will take for the sales force to re-engage on pricing with the existing accounts that have been trained and have experience or what percentage of existing accounts have been re-engaged versus your target? Thank you.

Mark Foley: Thanks, Navann. I don’t necessarily have a great number. Again, if you look at through the end of Q2, we said we were less than 2,000 accounts. So, I’m hoping that a number of these accounts have been contacted by the reps to inform them of the new price change to re-engage and then, as we said before, that re-engagement process in a given territory can take a little while as they work through each of their different accounts. And listen, I’m sure there’s some that may not be sort of, you know, in a position to re-engage. They might say, hey, come back in a little bit. But I would say most of the accounts that we’ve onboarded have been contacted and then the question is where are they at in that re-engagement process and I just don’t know. Thanks, Navann.

Operator: Ladies and gentlemen, this concludes our Q&A and today’s conference call. We’d like to thank you for your participation. You may now disconnect your lines.

Follow Revance Therapeutics Inc. (NASDAQ:RVNC)

Page 6 of 6